The article reflects on a previous investment in Sarepta (SRPT) that resulted in a significant loss due to a failed clinical trial, highlighting the inherent risks in biotech investments. Despite this setback, the author remains optimistic about the Bio-Tech ETF (XBI), which is showing strong upward momentum and could present buying opportunities on pullbacks.
The focus then shifts to Biogen (BIIB), which has demonstrated a strong uptrend and recently broke out of an ascending triangle pattern. The author identifies a target price of $240 in the coming months, with support expected just above $200. A longer-term analysis reveals that Biogen has broken a downtrend from its 2021 peak and surpassed its 200-week moving average, indicating bullish potential.
The article emphasizes the importance of risk management, suggesting that investors use the breakout level as support and monitor the stock's performance closely. With Biogen's shares up 21% year-to-date and 63% over the past year, the author believes the stock is on the verge of a significant turnaround, despite the challenges of picking individual biotech stocks